Ardena Group, the Belgian CDMO, has launched a new business unit to focus on the sale of chemical ingredients and intermediates for the life science industry. The new division is operating under Ardena LSI.
Ardena LSI will manufacture chemical ingredients for the development of drug products at the company's European GMP-certified plants. The product portfolio includes BDDE 98% GMP (1.4-Butanediol diglycidyl ether) and EDC-HCl Ultra Pure.
The ingredients can be used by pharmaceutical manufacturers in the development of drug products and for application in health care and cosmetics products like dermal fillers.
Fully integrated CDMO
Ardena LSI is part of the Ardena Group, a fully integrated contract manufacturing organisation offering of drug development services, full product analytical and bioanalytical support and regulatory dossier development. The company claims to be a leader in nanomedicine technology.
Ardena CEO, Harry Christiaens, commented: “We have built up extensive experience as a CDMO in the area of chemical synthesis and through Ardena LSI we are now harnessing that experience to manufacture high-quality chemical ingredients that are essential for pharmaceutical manufacturers in European markets.
“Customers need suppliers that truly understand the chemistry behind drug development, and we will work closely with them to understand their specific requirements and provide the ingredient quality and volumes that they need according to GMP guidelines.”
Since 2015, Ardena has seen more than 20% organic growth per year, fueled by the CDMO’s M&A strategy that has included four acquisitions in the past two years, most recently Netherlands-based ChemConnection and Sweden-based Syntagon.
